Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics, Inc. common stock is the subject of a beneficial-ownership report in which Empery Asset Management, LP and Ryan M. Lane each may be deemed beneficial owners of 21,247,856 shares, or 8.73%. They report shared voting and dispositive power over the shares, with no sole voting or dispositive power. The shares are held by funds for which Empery Asset Management serves as investment manager; Ryan M. Lane may be deemed a beneficial owner through his management relationship with the investment manager. The percentage uses 243,447,554 shares outstanding as of August 14, 2026. The report states that this does not itself admit that a reporting person beneficially owns shares attributed to another reporting person.
Outlook Therapeutics, Inc. (OTLK) received a Nasdaq notice on September 25, 2026, after its common stock’s closing bid price had been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on its listing. Outlook has 180 calendar days, through March 24, 2027, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before that date.
If Outlook does not regain compliance by then, it may qualify for an additional 180-day period if it meets the applicable market-value and other initial listing standards, except the bid-price requirement, and gives Nasdaq written notice of its intention to cure the deficiency. If it is ineligible for that period or Nasdaq Staff believes it cannot cure the deficiency, Nasdaq will notify Outlook that its stock is subject to delisting; Outlook may appeal.
Outlook Therapeutics, Inc. (OTLK) announced that it has established the wholesale acquisition cost for its product LYTENAVA™ in the United States at $485 per vial as of September 16, 2026. This disclosure sets an initial list price reference for LYTENAVA in the U.S. market.
Outlook Therapeutics, Inc. (OTLK) reported that its Chief Financial Officer, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026. The options have an exercise price of $0.63 per share and expire on September 1, 2036. The grant was made as an inducement to his employment under Nasdaq Listing Rule 5635(c)(4) and vests 25% on September 1, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to his continuous service.
Outlook Therapeutics, Inc. (OTLK) reports that its Chief Financial Officer, Kevin Michael Lundquist, has filed an initial statement of beneficial ownership on Form 3. The filing does not list any equity holdings, derivative positions, or transactions in Outlook Therapeutics securities by the reporting person.
Outlook Therapeutics, Inc. (OTLK) announced a planned chief financial officer transition. Lawrence A. Kenyon will cease serving as Chief Financial Officer, Treasurer, Corporate Secretary, principal financial officer and principal accounting officer effective September 1, 2026, and will remain in a non-executive role through September 30, 2026, after which he will also leave the Board and the Board size will be reduced to eight directors. The company states his departure is not due to any disagreement on accounting, financial reporting, operations, policies or practices.
The Board appointed Kevin Lundquist as Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer effective on the transition date. His employment agreement provides a $450,000 initial base salary, target bonus equal to 50% of base salary, and an option to purchase 500,000 shares, vesting over four years. Lundquist is entitled to specified cash severance, benefits continuation and, in a change in control context, full vesting of unvested time-vesting equity upon a qualifying termination. Kenyon’s separation agreement provides lump-sum cash severance based on 12 or 18 months of base salary plus additional amounts, full option vesting, and COBRA benefits, with enhanced terms if a change in control occurs within two months after his separation.
Outlook Therapeutics, Inc. (OTLK) is reported as the issuer of common stock held by institutional investors CVI Investments, Inc. and Heights Capital Management, Inc., which together are treated as "Reporting Persons." They report beneficial ownership of 24,713,908 shares of Outlook Therapeutics common stock, including 20,000,000 shares of common stock and additional shares issuable upon exercise of warrants, subject to a 9.99% beneficial ownership cap that limits warrant exercisability. Based on an indicated 242,672,554 shares outstanding as of the completion of a referenced offering, the Reporting Persons state that their holdings represent 9.9% of the outstanding common stock. Voting and dispositive power over these shares is shared, with Heights Capital Management acting as investment manager to CVI Investments and potentially exercising such powers, while both entities disclaim beneficial ownership beyond their pecuniary interest.
Outlook Therapeutics, Inc. (OTLK) reported continued operating losses while advancing LYTENAVA, its ophthalmic bevacizumab, toward broader commercialization. For the nine months ended June 30, 2026, net loss was $47.8 million versus $49.1 million a year earlier, with revenues, net of gross‑to‑net adjustments, of $(1.1) million compared with $1.5 million, driven largely by reserve changes and low early European sales. Operating cash outflow was $43.8 million, and cash and cash equivalents were $11.2 million at June 30, 2026.
Total assets were $26.2 million against $36.6 million of liabilities, leaving a stockholders’ deficit of $10.4 million. Management disclosed substantial doubt about the ability to continue as a going concern, citing recurring losses, a working capital deficit, and outstanding obligations including an unsecured promissory note to Atlas Sciences with $20.3 million of principal, accrued interest and exit fees outstanding and maturing in June 2027. The company has been funding operations primarily through equity, warrant exercises, and debt, including multiple 2026 offerings and a new at‑the‑market program.
Strategically, Outlook expanded its intellectual property portfolio and continued commercial rollout of LYTENAVA in Europe. Critically, in July 2026, after quarter‑end, the FDA approved LYTENAVA (bevacizumab‑vikg) as the first FDA‑approved ophthalmic bevacizumab for wet AMD in the United States, conferring 12 years of U.S. regulatory exclusivity. The company is preparing a U.S. launch before December 31, 2026 and subsequently raised approximately $51.1 million in an August 2026 follow‑on equity and warrant offering to help fund commercialization and general corporate purposes.
Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.